The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
Open accessAbstract
By fusing the extracellular domain of the natural killer (NK) cell receptor NKG2D to DAP12, we constructed a chimeric antigen receptor (CAR) to improve NK cell tumor responses. An RNA electroporation approach that provides transient expression of the CAR was adopted as a risk mitigation strategy. Expression of the NKG2D RNA CAR significantly augmented the cytolytic activity of NK cells against several solid tumor cell lines in vitro and provided a clear therapeutic benefit to mice with established solid tumors. Three patients with metastatic colorectal cancer were then treated with local infusion of the CAR-NK cells. Reduction of ascites generation and a marked decrease in number of tumor cells in ascites samples were observed in the first two patients treated with intraperitoneal infusion of low doses of the CAR-NK cells. The third patient with metastatic tumor sites in the liver was treated with ultrasound-guided percutaneous injection, followed by intraperitoneal infusion of the CAR-NK cells. Rapid tumor regression in the liver region was observed with Doppler ultrasound imaging and complete metabolic response in the treated liver lesions was confirmed by positron emission tomography (PET)- computed tomographic (CT) scanning. Our results highlight a promising therapeutic potential of using RNA CAR-modified NK cells to treat metastatic colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB
Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H., & Spies, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6879 · Cited by 1,028
Groh, V, Bahram, S., Bauer, S., Herman, A., Beauchamp, M., & Spies, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12445 · Cited by 1,017
Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells
Lanier, L. L., Corliss, B. C., Wu, J., Leong, C., & Phillips, J. H. (1998) · Nature · doi:10.1038/35642 · Cited by 904
Regulation of Ligands for the NKG2D Activating Receptor
Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 848
A Direct Role for NKG2D/MICA Interaction in Villous Atrophy during Celiac Disease
Hüe, S., Mention, J.-J., Monteiro, R. C., Zhang, S., Cellier, C., Schmitz, J., Verkarre, V., Fodil, N., Bahram, S., Cerf-Bensussan, N., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.018 · Cited by 759
Engineering Natural Killer Cells for Cancer Immunotherapy
Rezvani, K., Rouce, R., Liu, E., & Shpall, E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.012 · Cited by 453
Geller, M. A., Cooley, S., Judson, P. L., Ghebre, R., Carson, L. F., Argenta, P. A., Jonson, A. L., Panoskaltsis-Mortari, A., Curtsinger, J., McKenna, D., et al. (2011) · Cytotherapy · doi:10.3109/14653249.2010.515582 · Cited by 436
Chang, Y.-H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3558 · Cited by 329
Iliopoulou, E. G., Kountourakis, P., Karamouzis, M. V., Doufexis, D., Ardavanis, A., Baxevanis, C. N., Rigatos, G., Papamichail, M., & Perez, S. A. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0904-3 · Cited by 277
Are natural killer cells superior CAR drivers?
Klingemann, H. (2014) · OncoImmunology · doi:10.4161/onci.28147 · Cited by 270
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Mehta, R. S., & Rezvani, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00283 · Cited by 259
Müller, N., Michen, S., Tietze, S., Töpfer, K., Schulte, A., Lamszus, K., Schmitz, M., Schackert, G., Pastan, I., & Temme, A. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000082 · Cited by 253
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Töpfer, K., Cartellieri, M., Michen, S., Wiedemuth, R., Müller, N., Lindemann, D., Bachmann, M., Füssel, M., Schackert, G., & Temme, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1400330 · Cited by 249
Advantages and applications of CAR-expressing natural killer cells
Glienke, W., Esser, R., Priesner, C., Suerth, J. D., Schambach, A., Wels, W. S., Grez, M., Kloess, S., Arseniev, L., & Koehl, U. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00021 · Cited by 243
NKG2D ligands as therapeutic targets.
(2013) · Europe PMC (PubMed Central) · Cited by 218
Tricking the balance: NK cells in anti-cancer immunity
Pahl, J., & Cerwenka, A. (2017) · Immunobiology · doi:10.1016/j.imbio.2015.07.012 · Cited by 205
Chimeric NK-receptor–bearing T cells mediate antitumor immunotherapy
Zhang, T., Lemoi, B. A., & Sentman, C. L. (2005) · Blood · doi:10.1182/blood-2004-11-4365 · Cited by 157
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
Zhang, J., Basher, F., & Wu, J. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00097 · Cited by 156
Self-citationYang, Y., Lim, O., Kim, T. M., Ahn, Y., Choi, H., Chung, H., Min, B., Her, J. H., Cho, S., Keam, B., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0118 · Cited by 155
NKG2D signaling in cancer immunosurveillance
López‐Soto, A., Huergo-Zapico, L., Acebes‐Huerta, A., Villa-Álvarez, M., & Gonzalez, S. R. (2014) · International Journal of Cancer · doi:10.1002/ijc.28775 · Cited by 148
Zhang, T., Barber, A., & Sentman, C. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0130 · Cited by 128
Spear, P., Barber, A., Rynda‐Apple, A., & Sentman, C. L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103019 · Cited by 119
Lehner, M., Götz, G., Proff, J., Schaft, N., Dörrie, J., Full, F., Ensser, A., Muller, Y. A., Cerwenka, A., Abken, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031210 · Cited by 111
NKG2D CARs as Cell Therapy for Cancer
Sentman, C. L., & Meehan, K. R. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000029 · Cited by 111
Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Fernández, L., Metais, J.-Y., Escudero, A., Vela, M., Valentín, J., Vallcorba, I., Leivas, A., Torres, J., Valeri, A., Patiño-García, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0075 · Cited by 108
Song, D.-G., Ye, Q., Santoro, S. P., Fang, C., Best, A. J., & Powell, D. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.143 · Cited by 108
Barber, A., Rynda, A., & Sentman, C. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902000 · Cited by 105
VanSeggelen, H., Hammill, J. A., Dvorkin‐Gheva, A., Tantalo, D. G. M., Kwiecień, J. M., Denisova, G. F., Rabinovich, B. A., Wan, Y., & Bramson, J. L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.119 · Cited by 78
NKG2D CAR T‐cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors
Spear, P., Barber, A., Rynda‐Apple, A., & Sentman, C. L. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.17 · Cited by 72
Spear, P., Barber, A., & Sentman, C. L. (2013) · OncoImmunology · doi:10.4161/onci.23564 · Cited by 61
Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell–Treated Mice
Sentman, M.-L., Murad, J., Cook, W. J., Wu, M.-R., Reder, J., Baumeister, S. H. C., Dranoff, G., Fanger, M. W., & Sentman, C. L. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600769 · Cited by 61
Exploiting natural killer group 2D receptors for CAR T-cell therapy
Demoulin, B., Cook, W. J., Murad, J., Graber, D. J., Sentman, M.-L., Lonez, C., Gilham, D. E., Sentman, C. L., & Agaugué, S. (2017) · Future Oncology · doi:10.2217/fon-2017-0102 · Cited by 58
Barber, A. E., & Sentman, C. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900721 · Cited by 39
Compartmental Localization and Clinical Relevance of MICA Antibodies After Renal Transplantation
Li, L., Chen, A., Chaudhuri, A., Kambham, N., Sigdel, T. K., Chen, R., & Sarwal, M. (2010) · Transplantation · doi:10.1097/tp.0b013e3181bbbe4c · Cited by 35
Leveraging Natural Killer Cells for Cancer Immunotherapy
Grossenbacher, S. K., Aguilar, E. G., & Murphy, W. J. (2017) · Immunotherapy · doi:10.2217/imt-2017-0013 · Cited by 33
Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy
Lynn, R. C., & Powell, D. J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.162 · Cited by 16
Cited by
CAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
“[96] To date there are eight clinical CAR-NK studies focusing on solid malignancies such as brain, prostate, ovarian, pancreatic and lung cancer.”
BackgroundNatural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donne, R., & Lujambio, A. (2023) · Hepatology · doi:10.1002/hep.32740 · Cited by 631
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
mRNA vaccines manufacturing: challenges and bottlenecks
Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M., & Marques, M. P. C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.038 · Cited by 545
“In fact, this this system was successfully implemented in a phase I clinical trial designed to evaluate its potential in the treatment of colorectal cancers [64].”
Method
Metadata
- Authors
- Xiao, L., Cen, D., Gan, H., Sun, Y., Huang, N., Xiong, H., Jin, Q., Su, L., Liu, X., Wang, K., Yan, G., Dong, T., Wu, S., Zhou, P., Zhang, J., Liang, W., Ren, J., Teng, Y., Chen, C., & Xu, X. H.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 27
- Issue
- 6
- Pages
- 1114-1125
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2922879840
- Cited by
- 323
- References
- 40
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.